approval
saveTAFINLAR (DABRAFENIB MESYLATE) — FDA approval
community read0 votes
Sponsor: NOVARTIS. Form: CAPSULE. Route: ORAL
view source ↗Data sources
last refreshed 5mo ago
Found something off?
drug timeline · 8
- approvalTAFINLAR (DABRAFENIB MESYLATE) — FDA approvalMar 26, 2026 · 192d ago
- approvalTAFINLAR (DABRAFENIB MESYLATE) — FDA approvalMar 26, 2026 · 192d ago
- approvalTAFINLAR (DABRAFENIB MESYLATE) — FDA approvalApr 7, 2025 · 545d ago
- approvalTAFINLAR (DABRAFENIB MESYLATE) — FDA approvalApr 7, 2025 · 545d ago
- approvalTAFINLAR (DABRAFENIB MESYLATE) — FDA approvalMar 19, 2025 · 564d ago
- approvalTAFINLAR (DABRAFENIB MESYLATE) — FDA approvalMar 19, 2025 · 564d ago
- approvalTAFINLAR (DABRAFENIB MESYLATE) — FDA approvalMar 7, 2025 · 576d ago
- approvalTAFINLAR (DABRAFENIB MESYLATE) — FDA approvalMar 7, 2025 · 576d ago
same company · ±60 days · 6
- approvaldabrafenib mesylate ODT: TAFINLAR (DABRAFENIB MESYLATE) — FDA approvalJan 28, 2022
- approvalSpexotras: MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — FDA approvalJan 28, 2022
- approvalSpexotras: MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — FDA approvalJan 28, 2022
- approvalRestasis: SANDIMMUNE (CYCLOSPORINE) — FDA approvalMar 16, 2022
- approvalinclisiran: LEQVIO (INCLISIRAN SODIUM) — FDA approvalDec 22, 2021
- approvalCOSENTYX (SECUKINUMAB) — FDA approvalDec 22, 2021
comments(0)
5-min edit window · permanent after that